SNY officially canned idrabiotaparinux (a/k/a/ biotinylated idraparinux), an Arixtra-like anticoagulant that was nominally being tested for stroke prevention in AF: http://www.reuters.com/article/idCNLDE5BK02Y20091221 In the second subheading of #msg-41018456 from Aug 2009, it was noted that this program was on life support. Someone finally pulled the plug.